文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA I&T治疗期间定量SPECT/CT早期反应监测预测mCRPC患者总生存:瑞士全国前瞻性登记研究亚组分析

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-01

该单中心观察性研究纳入73例接受至少两周期177Lu-PSMA I&T治疗的mCRPC患者,于第1、2周期后行定量SPECT/CT。第2周期肿瘤总体积(TTV)稳定或下降与更长总生存(OS)相关(HR 0.28,95%CI 0.09-0.86,p<0.01),PSA稳定或下降与更长OS及PSA-PFS相关,TTV与PSA联合预后价值增强。

要点

  • 第2周期TTV稳定或下降与更长OS相关(HR 0.28,95%CI 0.09-0.86,p<0.01)。
  • PSA稳定或下降与更长OS(HR 0.21)和PSA-PFS(HR 0.34)相关。
  • TTV与PSA联合对OS和PSA-PFS的预后价值增强。

核心结论

  • 开始177Lu-PSMA I&T治疗六周后,TTV和血清PSA似乎是OS的良好预后指标。
  • TTV与PSA变化联合显示增强的预后价值,能更好地预测PSA-PFS。
  • 作者认为需要更大规模研究前瞻性使用TTV变化作为早期反应生物标志物,以实现更个性化的临床实践。

研究设计与样本

  • 单中心观察性研究,为瑞士全国前瞻性癌症登记研究的一部分,旨在评估177Lu-PSMA I&T在mCRPC患者中的安全性和有效性(EKNZ: 2021-01271)。
  • 纳入接受至少两个周期177Lu-PSMA I&T(每6周一次)治疗的mCRPC患者,2020年7月至2022年4月筛查111例,最终73例纳入数据分析。
  • 于第1和第2周期后48小时行定量SPECT/CT(Symbia Intevo,Siemens),采集头至大腿三个视野,5秒/帧,使用xQuant®重建(48i,1秒,10-mm Gauss)。
  • 使用SUV阈值3通过MIMencore®(版本7.1.3)半自动勾画PSMA阳性肿瘤总体积(TTV),计算第1至第2周期TTV、最高肿瘤SUVmax和总肿瘤SUVmean的变化,并分为稳定或下降与升高两组。
  • 每个治疗周期及随访至进展或死亡时评估血清PSA水平,采用Kaplan-Meier法(log-rank检验)分析变化与PSA-PFS和OS的相关性。

主要发现

  • 中位随访8.9个月(范围1.4-26.6个月)。
  • 第2周期TTV稳定或下降与更长OS相关(HR 0.28,95%CI 0.09-0.86,p<0.01)。
  • PSA稳定或下降与更长OS相关(HR 0.21,95%CI 0.07-0.62,p<0.01)及更长PSA-PFS相关(HR 0.34,95%CI 0.16-0.72,p<0.01)。
  • TTV与PSA联合对OS的预后价值增强(HR 0.09,95%CI 0.01-0.63,p<0.01),对PSA-PFS的预后价值增强(HR 0.11,95%CI 0.02-0.68,p<0.01)。
  • SUVmax或SUVmean下降与OS(p分别为0.88和0.7)及PSA-PFS(p分别为0.73和0.62)均无预后相关性。

关键数值与推荐

  • TTV变化分组:稳定或下降 vs 升高,基于SUV阈值3半自动勾画。
  • PSA变化分组:稳定或下降 vs 升高。
  • SUVmax或SUVmean变化分组:稳定或下降 vs 升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with 177Lutetium-PSMA I&T therapy. METHODS: Single-center, observational study, part of the prospective Swiss national cancer registry study investigating the safety and efficacy of [177Lu]Lu-PSMA I&T (EKNZ: 2021-01271) in mCRPC patients treated with at least two cycles of [177Lu]Lu-PSMA I&T 6-weekly. After the first and second cycle quantitated SPECT/CT (Symbia Intevo, Siemens) was acquired 48 h after injection (three fields of view from head to thigh, 5 s/frame) and reconstructed using xQuant® (48i, 1 s, 10-mm Gauss). Image analysis: The PSMA-positive total tumor volumes (TTV) were semi-automatically delineated using a SUV threshold of 3 with MIMencore® (version 7.1.3, Medical Image Merge Software Inc.). Changes in TTV, highest tumor SUVmax, and total tumor SUVmean between cycles 1 and 2 were calculated and grouped into a) stable or decrease and b) increase. Serum PSA levels were assessed at each therapy cycle and at follow-up until progression or death. Changes in TTV, PSA, SUVmax, and SUVmean were correlated with PSA-progression-free survival (PSA-PFS) and the overall survival (OS) using the Kaplan-Meier methodology (log-rank test). RESULTS: Between 07/2020 and 04/2022, 111 patients were screened and 73 finally included in the data analysis. The median follow-up was 8.9 months (range 1.4-26.6 months). Stable or decreased TTV at cycle 2 was associated with longer OS (hazard ratio (HR) 0.28, 95% confidence interval (CI) 0.09-0.86, p < 0.01). Similar, stable, or decreased PSA was associated with longer OS (HR 0.21; CI 0.07-0.62, p < 0.01) and PSA-PFS (HR 0.34; 95% CI 0.16-0.72, p < 0.01). Combining TTV and PSA will result in an augmented prognostic value for OS (HR 0.09; CI 0.01-0.63; p < 0.01) and for PSA-PFS (HR 0.11; CI 0.02-0.68; p < 0.01). A reduction of SUVmax or SUVmean was not prognostically relevant, neither for OS (p 0.88 and 0.7) nor for PSA-PFS (p 0.73 and 0.62, respectively). CONCLUSION: Six weeks after initiating [177Lu]Lu-PSMA I&T, TTV and serum PSA appear to be good prognosticators for OS. Combined together, TTV + PSA change demonstrates augmented prognostic value and can better predict PSA-PFS. Larger studies using TTV change prospectively as an early-response biomarker are warranted for implementing management change towards a more personalized clinical practice.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Neubauer MC, Nicolas GP, Bauman A, et al. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging. 2023. PMID: 38038755. doi:10.1007/s00259-023-06536-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。